Type 2 iodothyronine deiodinase is highly expressed in medullary thyroid carcinoma

Molecular and Cellular Endocrinology

Volumn 289, Issue 1-2, 2008, Pages 16-22

  Meyer, Erika L Souza ^a   Goemann, Iuri M ^a   Dora, José Miguel ^a   Wagner, Marcia S ^a   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Gene expression; Medullary thyroid carcinoma; TT cells; Type 2 deiodinase

Indexed keywords

CYCLIC AMP; DEXAMETHASONE; ENZYME; IODOTHYRONINE DEIODINASE TYPE 2; THYROID HORMONE RECEPTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA;

ADULT; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CYCLIC AMP; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODIDE PEROXIDASE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID HORMONES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 45049087608     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.04.009     Document Type: Article

References (50)

1. Araki O., Morimura T., Ogiwara T., Mizuma H., Mori M., and Murakami M. Expression of type 2 iodothyronine deiodinase in corticotropin-secreting mouse pituitary tumor cells is stimulated by glucocorticoid and corticotropin-releasing hormone. Endocrinology 144 (2003) 4459-4465
2. Arnaldi L.A.T., Borra R.C., Maciel R.M.B., and Cerutti J.M. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15 (2005) 210-221
3. Barrera-Hernandez G., Soo Park K., Dace A., Zhan Q., and Cheng S. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 140 (1999) 5267-5274
4. Bartha T., Kim S.W., Salvatore D., Gereben B., Tu H.M., Harney J.W., Rudas P., and Larsen P.R. Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine Deiodinase gene. Endocrinology 141 (2000) 229-237
5. Baur A., Buchfelder M., and Köhrle J. Expression of 5′-deiodinase enzyme in normal pituitaries and in various human pituitary adenomas. Eur. J. Endocrinol. 147 (2002) 263-268
6. Bianco A.C., Maia A.L., da Silva W.S., and Christoffolete M.A. Adaptive activation of thyroid hormone and energy expenditure. Biosci. Rep. 25 (2005) 191-205
7. Boye N., and Laurberg P. Deiodination of T4 to T3 and rT3 by microsomes from normal human thyroid tissue. Mol. Cell. Endocrinol. 37 (1984) 295-299
8. Carlomagno F., Salvatore D., Santoro M., de Franciscis V., Quadro L., Panariello L., Colantuoni V., and Fusco A. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 207 (1995) 1022-1028
9. Curcio C., Baqui M.M.A., Salvatore D., Rihn B.H., Mohr S., Harney J.W., Larsen P.R., and Bianco A.C. The human type 2 iodothyronine deiodinase is a seleno protein highly expressed in a mesothelioma cell line. J. Biol. Chem. 276 (2001) 30183-30187
10. Dentice M., Luongo C., Huang S., Ambrosio R., Elefante A., Mirebeau-Prunier D., Zavacki A.M., Fenzi G., Grachtchouk M., Hutchin M., Dlugosz A.A., Bianco A.C., Missero C., Larsen P.R., and Salvatore D. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc. Natl. Acad. Sci. 104 (2007) 14466-14471
11. De Souza Meyer E.L., Dora J.M., Wagner M.S., and Maia A.L. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentiation towards papillary carcinoma. Clin. Endocrinol. 62 (2005) 672-678
12. Dohán O., Baloch Z., Bánrévi Z., Livolsi V., and Carrasco N. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 86 (2001) 2697-2700
13. Elisei R., Pinchera A., Romei C., Gryczynska M., Pohl V., Maenhaut C., Fugazzola L., and Pacini F. Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. J. Clin. Endocrinol. Metab. 78 (1994) 867-871
14. Elisei R., Vivaldi A., Agate L., Ciampi R., Molinaro E., Piampiani P., Romei C., Faviana P., Basolo F., Miccoli P., Capodanno A., Collecchi P., Pacini F., and Pinchera A. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor ß messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J. Clin. Endocrinol. Metab. 90 (2005) 2403-2411
15. Gouveia C.H., Christoffolete M.A., Zaitune C.R., Dora J.M., Harney J.W., Maia A.L., and Bianco A.C. Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. Endocrinology 146 (2005) 195-200
16. Greene F.L., and Sobin L.H. The TNM system: our language for cancer care. J. Surg. Oncol. 80 (2002) 119-120
17. Hedinger C.E., Williams E.D., and Sobin L.H. Histological typing of thyroid tumors. WHO International Histological Classification of Tumours. 2nd ed. (1988), Springer-Verlag, Berlin pp. 5-6
18. Hosoi Y., Murakami M., Mizuma H., Ogiwara T., Imamura M., and Mori M. Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J. Clin. Endocrinol. Metab. 84 (1999) 3293-3300
19. Ishii H., Inada M., Tanaka K., Mashio Y., Naito K., Nishikawa M., and Imura H. Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue. J. Clin. Endocrinol. Metab. 52 (1981) 1211-1217
20. Kamiya Y., Murakami M., Araki O., Hosoi Y., Ogiwara T., Mizuma H., and Mori M. Pretranslational regulation of rhythmic type II iodothyronine deiodinase expression by β-adrenergic mechanism in the rat pineal gland. Endocrinology 140 (1999) 1272-1278
21. Kim B.W., Harney J.W., and Larsen P.R. Studies of the hormonal regulation of type 2 5′-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription-polymerase chain reaction. Endocrinology 139 (1998) 4895-4905
22. Kim B.W., Daniels G.H., Harrison B.J., Price A., Harney J.W., Larsen P.R., and Weetman A.P. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J. Clin. Endocrinol. Metab. 88 (2003) 594-598
23. Leboulleux S., Baudin E., Travagli J.P., and Schlumberger M. Medullary thyroid carcinoma. Clin. Endocrinol. 61 (2004) 299-310
24. Lemaire M., Bayens W., de Saint-Georges L., and Baugnet-Mahieu L. Thyroid hormone influence on the growth of hepatoma HW-165 in Wistar rats. Biomedicine 34 (1981) 133-139
25. Leuthauser S.W.C., and Guernsey D.L. Thyroid hormone affects the expression neoplastic transformation induced by DNA-transfection. Cancer Lett. 35 (1987) 321-326
26. Maia A.L., Harney J.W., and Larsen P.R. Pituitary cells respond to thyroid hormone by discrete, gene-specific pathways. Endocrinology 136 (1995) 1488-1494
27. Maia A.L., Kim B.W., Huang S.A., Harney J.W., and Larsen P.R. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J. Clin. Invest. 115 (2005) 2524-2533
28. Meyer E.L.S., Wagner M.S., and Maia A.L. Expressão das iodotironinas desiodases nas neoplasias tireoidianas. Arq. Bras. Endocrinol. Metabol. 51 (2007) 690-700
29. Mori K., Yoshida K., Kayama T., Kaise N., Fukazawa H., Kiso Y., Kikuchi K., Aizawa Y., and Abe K. Thyroxine 5-deiodinase in human brain tumors. J. Clin. Endocrinol. Metab. 77 (1993) 1198-1202
30. Morimura T., Tsunekawa K., Kasahara T., Seki K., Ogiwara T., Mori M., and Murakami M. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 146 (2005) 2077-2084
31. Mulligan L.M., Kwok J.B., Healey C.S., Elsdon M.J., Eng C., Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., Tunnacliffe A., and Ponder B.A. Germ-line mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 363 (1993) 458-460
32. Murakami M., Araki O., Morimura T., Hosoi Y., Mizuma H., Yamada M., Kurihara H., Ishiuchi S., Tamura M., Sasaki T., and Mori M. Expression of Type II iodothyronine deiodinase in brain tumors. J. Clin. Endocrinol. Metab. 85 (2000) 4403-4406
33. Murakami M., Araki O., Hosoi Y., Kamiya Y., Morimura T., Ogiwara T., Mizuma H., and Mori M. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142 (2001) 2961-2967
34. Murakami M., Kamiya Y., Morimura T., Araki O., Imamura M., Ogiwara T., Mizuma H., and Mori M. Thyrotropin receptors in brown adipose tissue: thyrotropin stimulates type II iodothyronine deiodinase and uncoupling protein-1 in brown adipocytes. Endocrinology 142 (2001) 1195-1201
35. Pacini F., Basolo F., Elisei R., Fugazzola L., Cola A., and Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am. J. Clin. Pathol. 95 (1991) 300-308
36. Ponder B.A. The phenotypes associated with RET mutations in the multiple endocrine neoplasia type 2 syndromes. Cancer Res. 59 (1999) 1736-1742
37. Puñales M.K., Graf H., Gross J.L., and Maia A.L. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J. Clin. Endocrinol. Metab. 88 (2003) 2644-2649
38. Rodríguez-Peña A. Oligodendrocyte development and thyroid hormone. J. Neurobiol. 40 (1999) 497-512
39. Salvatore D., Tu H., Harney J.W., and Larsen P.R. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98 (1996) 962-968
40. Schneider M.J., Fiering S.N., Pallud S.E., Parlow A.F., St. Germain D.L., and Galton V.A. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol. Endocrinol. 15 (2001) 2137-2148
41. Stahl J.H., Kendall S.K., Brinkmeier M.L., Greco T.L., Watkins-Chow D.E., Campos-Barros A., Lloyd R.V., and Camper S.A. Thyroid hormone is essential for pituitary somatotropes and lactotropes. Endocrinology 140 (1999) 1884-1892
42. Steinsapir J., Harney J., and Larsen P.R. Type 2 iodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes. J. Clin. Invest. 102 (1998) 1895-1899
43. Streckfuss F., Hamann I., Schomburg L., Michaelis M., Sapin R., Klein M.O., Köhrle J., and Schweizer U. Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice. Biochem. Biophys. Res. Commun. 18 (2005) 739-745
44. St. Germain D.L. Hormonal control of a low Km (typeII) iodothyronine 5′-deiodinase in cultured NB41A3 mouse neuroblastoma cells. Endocrinology 119 (1986) 840-846
45. Takano T., Miyauchi A., Ito Y., and Amino N. Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma. Thyroid 16 (2006) 615-618
46. Tannahill L.A., Visser T.J., McCabe C.J., Kachilele S., Boelaert K., Sheppard J.A., Franklyn N.J.L., and Gittoes N.J.L. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clin. Endocrinol. 56 (2002) 735-743
47. Wagner M.S., Morimoto R., Dora J.M., Benneman A., Pavan R., and Maia A.L. Hypothyroidism induces type 2 iodothyronine deiodinase expression in mouse heart and testis. J. Mol. Endocrinol. 31 (2003) 541-550
48. Wagner M.S., Wajner S.M., Dora J.M., and Maia A.L. Regulation of Dio 2 gene expression by thyroid hormones in normal and type 1 deiodinase-deficient C3H mice. J. Endocrinol. 193 (2007) 435-444
49. Zabel M., Seidel J., Kaczmarek A., Surdyk-Zasada J., Grzeszkowiak J., and Gorny A. Immunocytochemical characterization of two thyroid medullary carcinoma cell lines in vitro. Histochem. J. 27 (1995) 859-868
50. Zabel M., and Grzeszkowiak J. Characterization of thyroid medullary carcinoma TT cell line. Histol. Histopathol. 12 (1997) 283-289